Core Viewpoint - The article discusses the significant cash dividend announced by Sinovac Biotech, which will distribute $55 per share to shareholders, resulting in an astonishing dividend yield of 850% based on its last trading price of $6.47 before suspension [1][2][8]. Group 1: Dividend Announcement - On June 18, Sinovac Biotech's board announced a special cash dividend of $55 per share to be paid on July 7, along with plans for additional dividends of $19 and a potential third dividend ranging from $20 to $50 per share [4][8]. - The dividend yield of 850% is calculated based on the stock price of $6.47 prior to the suspension, highlighting the extraordinary nature of this payout [2][8]. Group 2: Financial Performance - Sinovac Biotech, a well-known biotechnology and vaccine production company, reported a net profit of $44.92 million in 2019 before the COVID-19 pandemic [11]. - The company saw a dramatic increase in revenue during the pandemic, with total revenue reaching $19.375 billion in 2021, a 3694% increase year-over-year, primarily driven by COVID-19 vaccine sales [13]. - However, post-pandemic, the company's revenue plummeted to $1.5 billion in 2022, a 92% decrease, and it reported a net loss of $99.91 million in 2023, a 187% decline year-over-year [14]. Group 3: Governance Issues - Sinovac Biotech has been embroiled in a seven-year power struggle, which began in 2015 between its founder and a rival shareholder, leading to a series of legal battles and governance disputes [15][17]. - The board's composition was challenged, and a recent ruling by the UK Privy Council replaced several board members, raising questions about the legitimacy of the current board [18]. - The ongoing governance issues have led to speculation that the large dividend payout may be a strategy to weaken potential opposition by depleting the company's cash reserves [18].
分红奇迹！股息率高达850%，核弹级分红来了！这家公司疫情期间爆赚，净利润大增7571%...